Company Update: Actavis plc (NYSE:ACT) – Actavis to Re-launch Generic Pulmicort RESPULES® Following Favorable Appeals Court Ruling

[PR Newswire] – DUBLIN, May 7, 2015 /PRNewswire/ — Actavis plc (ACT) today announced that it will immediately re-launch its generic version of AstraZeneca’s Pulmicort RESPULES® (budesonide inhalation suspension) 0.25 and 0.5 mg . . . → Read More: Company Update: Actavis plc (NYSE:ACT) – Actavis to Re-launch Generic Pulmicort RESPULES® Following Favorable Appeals Court Ruling Similar Articles: Company Update: Actavis plc (NYSE:ACT) – U.S. court weighs whether to let Actavis drop Alzheimer’s drug Stock Update (NASDAQ:AAPL): Apple asks U.S. appeals court to disqualify antitrust monitor Company Update (NYSE:ACT): (OFFICIAL)-UPDATE 1-Actavis’ superbug antibiotic gets U.S. approval (Feb. 25)